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Summary 
 
Alzheimer’s disease (AD) is a primary cause of dementia in the middle-aged and elderly 
worldwide. Animal models for AD are widely used to study the disease mechanisms as well as to 
test potential therapeutic agents for disease modification. Among the non-genetically 
manipulated neuroinflammation models for AD, lipopolysaccharide (LPS)-induced animal 
model is commonly used. This review paper aims to discuss the possible factors that influence 
rats’ response following LPS injection. Factors such as dose of LPS, route of administration, 
nature and duration of exposure as well as age and gender of animal used should be taken into 
account when designing a study using LPS-induced memory impairment as model for AD. 
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Introduction 
Alzheimer's disease (AD) was first described by Alois Alzheimer in 1906. It is a progressive 
neuropsychiatric disorder characterized by progressive loss of cognitive abilities (Wilkins and 
Brody 1969, Cavanaugh et al. 2014). It is a debilitating, ultimately fatal disease and is the 
primary cause of dementia in the middle-aged and elderly (Wilkins and Brody 1969, Fitzpatrick 
et al. 2005, Alzheimer’s Disease International 2009, Cavanaugh et al. 2014). 
 
The common initial symptoms are forgetfulness and difficulties with routine tasks. As the 
disease progresses, patients develop more severe memory loss, speech impairment, visual and 
spatial deficits, and loss of coordination and fine motor control (Rossor et al. 1996, Alzheimer’s 
Disease International 2009, Obermeyer et al. 2012). Besides the cognitive, sensory, and motor 
deficits caused by the disease progression, there are a number of behavioral and psychological 
symptoms related to dementia. These symptoms include agitation and aggression, wandering, 
disturbances in the sleep cycle, depression, anxiety, delusions and hallucinations (Ferri et al. 
2004, de Vugt et al. 2005, Obermeyer et al. 2012). AD reduces the life expectancy of those 
affected, with an average survival time after diagnosis of 5-7 years (Fitzpatrick et al. 2005, 
Ganguli et al. 2005). 
 
AD can be categorized into early and late onset. Early-onset AD (EOAD) typically begins 
between the ages of 30 and 60 years, and accounts for fewer than 5% of AD cases. The more 
common form, late-onset or sporadic AD (LOAD), presents after the age of 65 (Rossor et al. 
1996, Irvine et al. 2008).  
 
Risk factors for AD 
The single greatest risk factor for developing AD is age, with a risk of 10% for persons older 
than 65 years and nearly 50% for those older than 85 years (Rossor et al. 1996, Gatz et al. 2006, 
Chai 2007). 
 
Apart from age, genetic component is another risk factor for AD. Autosomal dominant familial 
AD (FAD), which is typically an EOAD, has been linked to mutations in genes encoding 
presenilin1 (PSEN1), presenilin2 (PSEN2), and beta-amyloid precursor protein (APP) (Chartier-
Harlin et al. 1991, Goate et al. 1991, Mullan et al. 1992, Schellenberg et al. 1992, Levy-Lahad et 
al. 1995, Sherrington et al. 1995). Inheritance of the apolipoprotein E type 4 allele (ApoE4) may 
also increase the risk of developing sporadic LOAD, though ApoE4 alone is neither necessary 
nor sufficient to cause AD (Corder et al. 1993, Strittmatter et al. 1993, Rossor et al. 1996, 
Sadigh-Eteghad et al. 2012). 
 
Non-genetically manipulated neuroinflammation models for AD 
The unique neuropathological hallmarks of AD are extracellular accumulation of beta-amyloid 
(Aβ) peptide and intracellular accumulation of hyperphosphorylated tau protein or neurofibrillary 
tangles (NFTs,) (Hardy and Selkoe 2002, Iqbal and Grundke-Iqbal 2006). A true model that fits 
the inflammation hypothesis of AD is an aged animal (older than 22 months) that manifests early 
chronic neuroinflammation lasting more than 7 days prior to hyperphosphorylation of tau and Aβ 
plaque deposition (Burton and Johnson 2012).   
 
The intracellular accumulation of Aβ, especially Aβ1-42, has been shown to precede the 
formation of extracellular amyloid deposits in subjects with AD and trisomy 21 (Gouras et al. 
2000), in brains of young Tg mice (8-month-old) harboring APP with three FAD-linked 
mutations (KM670/671NL, E693Q, and V7171) and the PS1 mutation M146L (Wirths et al. 
2001), and in the brains of older Tg mice (17-month-old) harboring various FAD-linked PS1 
mutations (Chui et al. 1999). Based on these findings, Sheng et al. (2003) concluded that 
intracellular accumulation of Aβ may be an early stage of a process that may eventually lead to 
extracellular amyloid deposits and the formation of plaques. 
 
However, other potential rodent models of AD that present with early neuroinflammation in the 
disease process and are not genetically manipulated by mutations related to Aβ or tau production 
are also commonly used. These include lipopolysaccharide (LPS)-, polyI C-, streptozotocin-, 
okadaic acid- and colchicine-induced neuroinflammation. LPS-induced neuroinflammation 
represents the current standard paradigm to study neuroinflammation both in vivo (Hauss-
Wegrzyniak et al. 1998; Sheng et al. 2003; Anaeigoudari et al. 2016) and in vitro (Candiracci et 
al. 2012). There are several other non-genetically manipulated rat models of AD which are not 
limited to induced neuroinflammation. For example, the ferrous amyloid buthionine (FAB) rat 
model (Lecanu and Papadopoulos 2013), the sodium azide model (Szabados et al. 2004) and the 
Samaritan AD rat model (Petrasek et al. 2016). This review focuses only on the widely studied 
LPS-induced cognitive deficit in rats and the possible factors that can influence rats’ response to 
LPS. 
 
Lipopolysaccharide  
LPS is used worldwide in experimental in vitro and in vivo models of neuroinflammation and 
amyloidosis (Miklossy 2008). LPS-induced systemic inflammation is used in a number of 
neurodegenerative diseases; AD (Hauss-Wegrzyniak et al. 1998; Sheng et al. 2003; 
Anaeigoudari et al. 2016), Parkinson disease (Gao et al. 2002; Whitton 2007), amyotrophic 
lateral sclerosis (Zhao et al. 2004) and multiple sclerosis (Walter et al. 2006).  
 
LPS is a component of the outer membrane of gram-negative bacteria. It is a potent endotoxin 
and is highly resistant to degradation by mammalian enzymes thus providing a persistent 
inflammatory stimulus (Ohanian and Schwab 1967) that produces proinflammatory cytokines. 
These proinflammatory cytokines activate both the neuroimmune and neuroendocrine systems 
(Maitra et al. 2012) that result in similar responses as produced by behavioural stress (Oitzl et al. 
1993). 
 
LPS produces a wide range of non-specific behavioural effects collectively termed ‘sickness 
behaviours’ (Klein and Nelson 1999). These behaviours include reduction in activity, reduction 
in exploration, decreased social interaction, fever, reduction in consumption of food and drink, 
hypersomnia, activation of the hypothalamic–pituitary–adrenal (HPA) axis and causing increased 
sympathetic activation (Hart 1988, Kebt et al. 1992, Pugh et al. 1998). 
 
Mechanism of action of LPS in the central nervous system (CNS) 
A direct action of LPS within the CNS is an important possibility (Elmquist et al. 1997). It is 
possible that LPS can access the brain directly via peripheral nerve transduction (Hansen et al. 
2000), the circumventricular organs (Blatteirs et al. 1992), area postrema (Ericsson et al. 1994) 
or even at the level of the hypothalamus (Yasuda and Greer 1978, Zhang et al. 2000). 
Mechanism of LPS action in CNS is shown in Fig. 1. 
 
LPS binds CD14 on microglia membranes forming the LPS-CD14 complex which then interacts 
with toll-like receptor (TLR)-4 (Hailman et al. 1994, Lehnardt et al. 2003). TLR-4, in turn, 
activates microglia by initiating signal transduction cascades leading to rapid transcription and 
release of proinflammatory cytokines including interleukin (IL)-1, IL-6, IL-12, IL-17A, IL-18, 
p40, inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α (TNF-α) (Rivest 2009, 
Bossu et al. 2012, Sun et al. 2015); chemokines such as CCL2, CCL5, and CXCL8; complement 
system proteins such as C3, C3a, and C5a receptors (Rivest 2009); and anti-inflammatory 
cytokines such as IL-10 (Mizuno et al. 1994) and transforming growth factor-β (TGF-β) 
(Welser-Alves and Milner 2013). It has been shown that the level of expression of TNF-α, IL-1β, 
and IL-6 in the hippocampus was increased compared to controls after three days of LPS 
administration (Daulatzai 2016). 
 
Proinflammatory cytokines are key molecules that modulate immune responses. Their lack of 
reversibility in chronic inflammation would enhance dyshomeostasis (Ghosh et al. 2015). 
Chronic inflammation is characterized by long-standing activation of microglia that sustains the 
release of inflammatory mediators, leading to an increase of oxidative and nitrosative stress. This 
perpetuates the inflammatory cycle (Tansey et al. 2007), further prolonging the inflammation 
(Schmid et al. 2009) that is detrimental for several neurodegenerative diseases (Block and Hong 
2005). 
 
An excessive inflammatory response is characterized not only by elevated proinflammatory 
cytokines, but also by increases in mitochondrial dysfunction, reactive oxygen species (ROS), 
and nitric oxide (NO). Consequently, there may be damage to the systemic vascular endothelium, 
redox-glutathione depletion, and mitochondrial respiratory dysfunction causing reduction in ATP 
and O2 consumption. Hence, inflammation and oxidative stress are intertwined (Exline and 
Crouser 2008, Bivalacqua et al. 2009, Victor et al. 2009; Galley 2011, Lowes et al. 2013) and 
have been implicated in the pathophysiology of AD.  
 
It has been shown that inflammatory cytokines such as IL-1β, IL-6, TNF-α and TGF-β can 
augment APP expression (Buxbaum et al. 1992, Hirose et al. 1994) and Aβ formation (Blasko et 
al. 1999). It has also been reported that cytokines are able to transcriptionally upregulate β-
secretase mRNA, and protein and enzymatic activity (Sastre et al. 2003). β-secretase is a key 
rate-limiting enzyme that initiates Aβ formation (Vassar 2001). Without β-secretase, Aβ 
synthesis is either abolished or considerably reduced (Walter et al. 2001).  
 
It has been pointed out in the literature that LPS-induced inflammation promotes AD pathology 
by altering Aβ transport at the blood brain barrier (BBB) (Jaeger et al. 2009) and decreasing the 
central clearance of Aβ (Erickson et al. 2012). Alteration of BBB effectively increases brain 
influx of Aβ but decreases its efflux (Jaeger et al. 2009). The level of expression of Aβ in the 
hippocampus is shown to increase (compared with controls) after seven days of LPS 
administration (Daulatzai 2016). 
 
LPS-induced neuronal cell death could be the result of cyclooxygenase-2 (COX-2) and 
extracellular signal-regulated kinase (ERK) activation (Lee et al. 2008). COX-2 is barely 
detectable under normal physiological conditions, but can be induced rapidly and transiently by 
proinflammatory mediators and mitogenic stimuli, thereby mediating deleterious effects in the 
neurodegenerative disorders (Pasinetti et al. 2001). In Alzheimer brain, COX-2 is notably up-
regulated, which seems to be associated with Aβ plaque formation (Pasinetti et al. 1998, 
Hoozemans et al. 2001, Pasinetti et al. 2002). Conversely, deposition of Aβ in the brain has been 
reported to trigger an inflammatory response associated with the neuropathophysiology of AD 
(Paris et al. 2002). Jang and Surh (2005) showed that Aβ-induced apoptosis is associated with 
COX-2 up-regulation through activation of NF-κB, which is mediated by upstream kinases 
including ERK and p38 mitogen-activated protein kinases (MAPK).  
 
LPS may disrupt the consolidation of certain memory processes.  Acute administration of LPS 
prior to training impairs contextual-cue fear conditioning, a hippocampal-dependent learning 
paradigm (Pugh et al. 1998); while chronic infusion of LPS has been found to impair spatial 
memory (Hauss-Wegrzyniak et al. 1998 and 2000)  and induce memory and learning deficits 
analogous to AD cognitive decline (Lee et al. 2008). Systemic LPS administration leads to 
selective hippocampal impairment in context-object discrimination but not spatial memory 
(Czerniawski et al. 2015). Major cognitive findings in LPS-treated rats are summarized in Table 
1. 
 
Animal Response Following LPS Administration 
There are a number of factors that can influence animal response to LPS injections, including 
dose, nature of exposure, route of administration, duration of exposure, age and gender of the 
animals.  
 
Dose of LPS  
Houdek, et al. (2014) demonstrated that direct LPS infusion into the fourth ventricle of the male 
rat brain resulted in a dose-dependent response of activated microglia and astrocyte. Very low-
dose LPS infusion (0.05 ng/hr) was sufficient to induce neuroglial activation while moderate and 
high doses (50 ng/hr and above) were required to induce significant loss of choline 
acetyltransferase (ChAT)-positive cells in the basal forebrain. 
 
Nature of LPS exposure 
Pugh et al. (1998) demonstrated that 0.125 and 0.25 mg/kg LPS interfered with contextual fear 
conditioning, while 0.5 mg/kg had no effect. Similarly, LPS differentially affects the 
hypothalamic–pituitary axis in that a higher dose of LPS stimulates the sustained release of 
corticosterone (Nguyen et al. 1998, Pugh et al. 1998). This appears to be only true for acute 
exposure to LPS; repeated injections of LPS have no such effect on corticosterone levels 
(Takemura et al. 1997).  
 
Later studies by Shaw et al. (2001 and 2005) showed that a single injection of LPS impaired 
escape latency in both the acquisition and retention phases of hippocampal-dependent learning–
spatial learning while a daily injection did not. Repeated LPS exposure also resulted in lower IL-
1β activation; this may be due to an alteration in peripheral sympathetic responsiveness (Zhang 
et al. 2000). It is possible that repeated exposure to LPS produces a tolerance effect, as suggested 
by the lower IL-1β activation, which may account for the observed behavioural changes in the 
study. 
 
Repeated endotoxin exposure has long been known to result in a tolerance-like phenomenon 
(Habicht 1981). The acute administration of LPS has been better characterized, and a few studies 
have examined the effects of repeated LPS injections upon behaviour or how endotoxin tolerance 
may be observed in terms of an animal’s learning. Kobayashi et al. (2002) demonstrated at least 
one of the molecular bases for the tolerance-like phenomenon. They showed that repeated 
stimulation of the TLR results in the induction of IL-1 receptor associated kinase-M (IRAK-M), 
negatively regulating the TLR signaling cascade by halting IRAK’s interaction with TNF-
receptor associated factor-6 (TRAF6). This mechanism of tolerance may be an adaptive event 
critical in avoiding endotoxic shock.  
 
Route of LPS administration  
The most common routes of LPS administration using LPS-induced cognitive impairment rat 
model are intraperitoneal and intracerebroventricular. However, we found no studies that 
explicitly compare different routes of LPS administration with the effect of cognitive function in 
rats. 
Duration of LPS exposure 
Bordou and colleagues (2014) investigated the role of duration of exposure to LPS on the 
neuroinflammatory response to LPS. Male rats received continuous infusion of picomolar levels 
of LPS (or artificial CSF as control) into their fourth ventricle for either 3 or 8 weeks. Longer 
duration of exposure to LPS infusion further increased the elevated levels of IL-1-α, IL-2, IL-4, 
IL-5, IL-6, IL-12, IL-13, and GM-CSF. This study provides evidence of the influence of 
chronicity of infection on neuroinflammatory responses in certain brain regions, such as locus 
coeruleus, that undergo significant cell loss in the early stages of AD (Grudzien et al. 2007). 
However, the study did not investigate the role of duration of exposure to LPS on cognitive 
behaviour. 
 
In a study of Zhu et al. (2014), the results demonstrated that 7 days of LPS administration 
significantly increased the latency to the platform and decreased the proportion of time spent in 
the target quadrant during Morris water maze test, compared to 3 days of LPS administration. 
Increased expression of Aβ in the hippocampus was observed following administration of LPS 
for 7 days but not for 3 days, indicating that the increased expression of Aβ may be a major 
factor in the pathogenesis of cognitive dysfunction. 
 
Age of animal during LPS exposure 
Age appears to be an important factor influencing the behavioral responses to LPS. Prenatal 
(Bakos et al. 2004) and early postnatal (Fan et al. 2005, Pang et al. 2006) LPS exposure has been 
shown to induce poor neurobehavioural performance and is frequently used to model diseases 
such as schizophrenia and autism (Powell 2010; Meyer 2014; Waterhouse et al. 2016). 
 
Younger animals seem to be affected to a lesser degree, at a slower pace and do not show speed 
decrement on day one as shown by the year-old mice (Sparkman et al. 2005). Bardou and 
colleagues (2014) investigated the age of exposed rats on the neuroinflammatory response to 
LPS. Male rats at three age groups of young (3 months), middle-aged (9 months), and aged (23 
months) received continuous infusion of picomolar levels of LPS (or artificial CSF as control) 
into their fourth ventricle. Among all cytokines, TNF-α increase in response to LPS infusion was 
similar in the different age groups. However, in contrast to young rats, IL-1β did not significantly 
increase after 3 weeks of infusion in middle-aged and aged rats. Instead, aged rats had 
significantly increased IFN-γ compared to younger rats. In another study, however, LPS 
administration in aged rats induced prolonged neuroinflammation and astrogliosis in the 
hippocampus (dentate gyrus) with higher mRNA expression and protein levels of TNF-α and IL-
1β (Fu et al. 2014). 
 
Age is also an important factor to develop tolerance-like phenomenon (Habicht 1985). Splenic 
lymphocytes of 12-month and 24-month-old animals are less likely to develop tolerance 
following repeated endotoxin exposure when compared to splenic lymphocytes obtained from 
young animals. Thus, old animals exposed to long-term LPS seem to be an ideal model of AD. 
 
Gender  
Almost all rat studies of LPS-induced cognitive impairment model used male rats. Studies in 
mice, however, demonstrated a heightened HPA response to LPS in females (Frederic et al. 
1993, Spinedi et al. 1997), which may have important behavioural implications. 
 
Conclusion 
Extra caution is needed before extrapolating preclinical findings using LPS to clinical situations. 
Sensitivity to LPS and the consequent production of proinflammatory cytokines is much greater 
in humans compared to rodents (Warren et al. 2010). Thus, the doses of LPS given in most 
rodent models are about 103– 104 times the dose required to induce severe disease in humans 
(Sauter et al. 1980, Taveira et al. 1993). Other factors such as route of administration, nature and 
duration of exposure as well as age and gender of animal used should be taken into account when 
designing a study using LPS-induced memory impairment as model for AD. 
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Table 1. Major cognitive findings in LPS-treated rats  
 
Gender and strains  LPS dosage (mode 
of administration) 
LPS injection 
(duration) 
Major cognitive findings (Behaviour test) Reference 
Adult male Sprague 
Dawley rats (3 months) 
0.25 µg/h (i.c.v.) Single injection 
daily for 28 days 
Chronic infusion significantly impaired 
alternation performance  (T maze) 
 
Hauss-
Wegrzyniak et al. 
1998 
Young male and female 
Hooded Long Evans rats  
 
Adult male Albino 
Sprague Dawley rats  
0.125, 0.25 and 0.50 
mg/kg (i.p.) 
Single injection LPS administration after conditioning 
selectively impaired contextual fear 
conditioning in both young and adult rats of 
two different strains. It had no effect on 
auditory-cue fear conditioning (Contextual fear 
conditioning) 
 
Pugh et al. 1998 
Adult male Wistar rats 0.5–5 μg/2 μl (i.c.v.) 
 
Single injection Significantly impaired spontaneous alternation 
behavior but no change in the number of arm 
entries and impaired spatial memory 
impairments (Y maze and Morris water maze) 
 
Yamada et al. 
1999 
Adult  male Sprague 
Dawley rats (6 months)  
0.25 µg/h (i.c.v.) Single injection 
daily for 37 days 
Chronic infusion significantly impaired 
alternation performance but had no effect upon 
object recognition performance (T maze and 
object recognition) 
 
Hauss-
Wegrzyniak et al. 
2000 
Adult male Wistar rats  100 µg/kg (i.p.) Single injection 
daily for 5 days 
LPS impaired escape latency in both the 
acquisition and retention phases of the Morris 
water maze test (Morris water maze) 
 
Shaw et al. 2001 
Adult male Wistar rats 250 µg/kg (i.p.) Single injection LPS impaired hippocampal-dependent spatial 
learning (Water maze) 
 
Shaw et al. 2005 
Sprague Dawley pups of 
both sexes (Day 5) 
1 mg/kg (i.c.v.) 
 
Single injection 
daily for 3 days 
The number of electric foot shocks needed to 
retain the rat on the safe board was increased 
Fan et al. 2005 
significantly in the LPS-injected group at 
postnatal day 20. LPS also reduced the 
retention latency to step down from the board 
the next day as compared to the latency in the 
control group. (Passive avoidance memory 
retention test) 
 
Sprague Dawley pups of 
both sexes (Day 5) 
10 µg (i.c.v.) 
 
Single injection The number of electric foot shocks required to 
retain the rat on the safe board was 
significantly increased in the LPS-injected 
group at postnatal day 20. In the test trial the 
next day, the retention latency to step down 
from the board was remarkably less than 
control (Passive avoidance memory retention 
test) 
 
Pang et al. 2006 
Adult male Wistar rats 100 μg/kg (i.p.) Single injection LPS impaired recognition memory (Object 
recognition) 
 
Hennigan et al. 
2007 
Adult male Wistar rats 5 mg/kg (i.p.) Single injection The behavioural assessment was done 7 days 
and 10 months post-LPS injection. Both 
resulted in discriminative deficits not 
associated to any spatial memory deficit  
(Open field with objects and Morris water 
maze) 
 
Bossù et al.. 2012 
Adult male Wistar rats 5 µg/5 µl (i.c.v.) 
 
Single injection LPS impaired working memory and long-term 
memory (Y maze) 
 
Joshi et al. 2014 
Adult male Wistar rats 1 mg/kg (i.v.) Single injection LPS impaired cognitive performance  
(Barnes maze and inhibitory avoidance test)  
  
Vasconcelos et al. 
2014 
Adult male Wistar rats 250 μg/kg (i.p.) Single injection LPS for 7 days caused higher memory Zhu et al. 2014 
daily for 3 or 7 days impairment compared to LPS for 3 days  
(Morris water maze) 
 
Adult male Sprague 
Dawley rats 
167 µg/kg (i.p.) Single injection LPS significantly impaired context-object 
discrimination but not spatial memory and 
object recognition (water maze task, context–
object discrimination, and novel object 
recognition)  
 
Czerniawski et al. 
2015 
Adult male Wistar rats 1 mg/kg (i.p.) Single injection LPS impaired passive avoidance memory 
retention 
  
Anaeigoudari et 
al. 2015 
Aged male Sprague 
Dawley rats (18 months) 
500 μg/kg (i.p.) Single injection LPS impaired cognitive performance (Trace 
fear conditioning and Y maze) 
 
Sun et al. 2015 
Adult male Wistar rats 1 mg/kg (i.p.) Single injection Time latency and traveled path were higher in 
LPS group than the control group (Morris 
water maze) 
 
Anaeigoudari et 
al. 2016 
Adult male Sprague 
Dawley rats 
50 µg/5 µl (i.c.v.) Single injection Injection of LPS into lateral ventricle caused 
learning and memory impairment (Y maze and 
Morris water maze) 
Song et al. 2016 
 
i.c.v., intracerebroventricular; i.p., intraperitoneally; i.v., intravenous. 
 
 
 
 
Fig. 1. Mechanism of LPS action in CNS 
